I agree completely.......people just showing their ignorance. No place for it on a stock board - it's a no win situation for either side.....
People need to put their shares into a cash account if you don't want them lent out. Shares can be borrowed on any margin account.......
I was just revisiting Ms. Ware's history in the bio world. Truly impressive - how in the heck did Cytrx obtain her services. The ONLY way she agreed to coming on board was if she could add to her already incredible accomplishments in product strategy and marketing. Check out her "Experience" on her LinkedIn page:
If she is confident in reproducing her accomplishments with Aldoxorubicin, then we are in for one incredible ride........gltal
We should readout on Ebola in the next few months. That could go a long ways towards validating our infectious disease platform. But what I look forward to is the Mers data which has kind of been lost in the whole Zika media explosion. Saudi's have the resources to get behind this thing if positive results begin to emerge....then the coup de grace - INO 3112 imo.........
Not quite Dman but remembering the old days & good times. Little Inovio has grown up and is a force to be reckoned with imo..... This year will be a good one - lot's of data read outs and we'll finally get our questions answered about how they plan to move 3112 into Phase 3.... Oh sorry I meant 3100 :)
Also new partner coming in before June - you can bet on it.....gl guys
I've said for a year now that they will not do a $100 million dollar phase 3 with existing data from our phase2. It was good but not good enough to risk all the time & money & reputation that a failed phase 3 would bring. This delay is a product of just waiting for 3112 data to mature enough for use in a possible 2b or phase3 of 3100. I may be wrong on specifics, but I just don't see them basing a 3 year phase 3 on existing data.....we shall see glta
I think his lawyers have finally succeeded in impressing upon him the importance of keeping a lid on things that tend to shoot out of his mouth.....
Everything is agenda driven these days.......his history is less than stellar - as is Jeffries
From Tip Ranks:
"If you copied Chris Howerton's ratings since 2015 and opened each position for the duration of 1 Year , then 40% of your transactions would have been profitable with an average return of -13.1%...."
Here's the latest info from the Jan. 7, 2016 S-3/A........just slightly changed from your post:
"As of December 31, 2015, we held rights in four granted U.S. patents, 55 granted foreign patents, three pending U.S. applications, and twenty-two pending foreign patent applications covering aldoxorubicin and related technologies. Our intellectual property holdings relating to aldoxorubicin and related technologies include an exclusive license from KTB Tumorforschungs GmbH to U.S. and foreign patents and patent applications. Patents and applications that cover pharmaceutical compositions of aldoxorubicin, processes for their production, and their use in treatment methods (e.g., cancer, (including glioblastoma), viral diseases, autoimmune diseases, and acute or chronic inflammatory diseases) have unextended patent terms expiring between June 2020 and June 2034. Additionally, we have three pending U.S. provisional patent applications covering our LADRTM technology and DK049. .."
You do know that Doxo-emch and Inno -206 ARE Aldoxorubicin? Dr. Kratz created Doxo-emch in 2007 that subsequently became aldoxorubicin. Cytrx bought Innovive which owned Inno-206 (amongst others) in June 2008. Both have been rolled into what is now known as Aldoxorubicin.......gl
links: Expert Opin Investig Drugs. 2007 Jun;16(6):855-66.
DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.
CytRx’s INNO-206 Rapidly Shrinks Human Tumors in an Animal Model of Multiple Myeloma
Groundbreaking Statistically Significant Interim Results Expand INNO-206’s Potential Therapeutic Indications
yeah.....the use of Dox is viewed by many as a barbaric treatment regimen and irrelevant in the present oncology conversations. However, it remains to be used prolifically in oncology therapies throughout the world and won't be going anywhere soon imo........
Paris, Nick......I don't see that much either. But, believe me, the market is very scary right now and everyone is jumping on the fear wagon. I just deposited another 15k yesterday just because of that. I didn't bite on the 1.88 today but I was damn close. Over the years(including this stock) I have learned to be patient. I do see the market correcting 20% possibly.
That said, my conviction remains on Aldo and like others have said, I don't think they could recruit Ms. Ware if they didn't have the data to impress. The PR says it all...
"Ms. Ware was a Senior Director of Oncology and was responsible for the initial commercial launch of Avastin in the U.S., which reached $1 billion in sales during its first year on the market. Prior to this, she was head of Herceptin marketing and held a number of other positions in the commercial organization. Later, Ms. Ware was a Senior Director in the Product Portfolio Management Group, managing approximately 20 senior leaders responsible for building and leading the cross-functional drug development teams that developed and implemented strategic plans and guided the drug development processes for all oncology products at Genentech..."
I am still excited about the next few months and I will hold all my shares. I've seen this numerous times( stock beat down) just previous to successful drug launches. Remember we're just pawns in this market and when the big boys decide it's time to let it go, I'll be riding that same train.....I'm sticking with my conviction.....gl guys.
It's called the black box....This is latest data that is only known to the investigators and company. Qualified suitors with serious offers need to sign a NDA to get a look at it and the buyout/partnership negotiations begin. IMO, they need a partner on this. They're not set up for all that entails marketing a drug on their own. This capital raise gives them solid footing for negotiations and it will allow them to increase the scope of their trials for off label indications etc.......I guess we'll al know in a few months.
Can't spell, can't formulate a sentence and have no idea on how to determine MC.....let me know when I should sell